Wilms' tumour gene 1 (WT1) in human neoplasia
Open Access
- 26 May 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 19 (8), 1318-1323
- https://doi.org/10.1038/sj.leu.2403817
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic SyndromeActa Haematologica, 2004
- WT1 and glomerular functionSeminars in Cell & Developmental Biology, 2003
- The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemiaBlood, 2003
- Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patientsLeukemia, 2002
- Overexpression of the Wilms' tumor gene WT1 in de novo lung cancersInternational Journal of Cancer, 2002
- Cancer Immunotherapy Targeting Wilms’ Tumor Gene WT1 ProductThe Journal of Immunology, 2000
- GATA-1 Transactivates the WT1 Hematopoietic Specific EnhancerJournal of Biological Chemistry, 1995
- An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumorCell, 1990
- Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor geneCell, 1990
- Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locusCell, 1990